News


August 14th, 2017

Positive feedback from FDA reviewers in response to Pre-IND meeting package

Vancouver, British Columbia – August 14th, 2017 – Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a unique platform of immunotherapies designed to restore the body’s innate immune system, reports positive and informative feedback from the US Food and Drug Administration (FDA) in response to Qu’s first Pre-IND meeting package submission. The […]

READ MORE >
August 2nd, 2017

Treatment with Qu Biologics’ Novel Immune Therapy for Ulcerative Colitis Results in High Clinical and Endoscopic Response Rates and Histological Improvement

Vancouver, British Columbia – August 2nd, 2017 – Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a unique platform of immunotherapies designed to restore the body’s innate immune system, reports high clinical and endoscopic response rates in its recently completed Phase 2, open-label, dose ranging trial in study participants with moderate to […]

READ MORE >
August 2nd, 2017

Qu Biologics invited to present at US National Cancer Institute (NCI) Conference

Vancouver, British Columbia – July 12th, 2017 – Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a unique platform of immunotherapies designed to restore the body’s innate immune system, is pleased to announce that CEO Dr. Hal Gunn, was invited to present at the US National Cancer Institute’s Microbial-Based Cancer Therapy Conference […]

READ MORE >
July 7th, 2017

More Qu Biologics international research presentations

Dr Hal Gunn, CEO of Qu Biologics, has been invited to present at the US National Cancer Institute (NCI) Conference on Microbial-Based Cancer Therapy. His topic for presentation is “Site-Specific Immunomodulators: Harnessing the Intrinsic Immune Capacity to Prevent and Fight Malignancy”.  Initiated by the NCI Office of Cancer Complementary and Alternative Medicine, the aim of this […]

READ MORE >
May 24th, 2017

Qu Biologics Publishes Proof-of-Principle Data for Promising New Treatment for Chronic Obstructive Pulmonary Disease (COPD)

Vancouver, British Columbia – May 23, 2017 – Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs) designed to “reboot” the body’s innate immune system, announces the peer-reviewed publication of proof of principle data in chronic obstructive pulmonary disease (COPD) in the journal, Respiratory Research.  The study demonstrates success with Qu Biologics’ QBKPN SSI in reducing […]

READ MORE >
May 4th, 2017

Qu Biologics invited to present Research Data at International Scientific Meetings

Vancouver, British Columbia – May 3rd, 2017 – Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a unique platform of immunotherapies designed to restore the body’s innate immune system, is pleased to announce that Qu Biologics’ scientists will be presenting their research findings at several upcoming international scientific meetings. The presented data […]

READ MORE >
April 19th, 2017

High Response and Remission Rates in Anti-TNFα Naïve Patients Treated with Qu Biologics’ Novel Immune Therapy for Crohn’s Disease

Vancouver, British Columbia – April 19th, 2017 – Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a unique platform of immunotherapies designed to restore the body’s innate immune system, reports high response and remission rates in anti-TNFα naïve patients in its recently completed randomized, placebo controlled trial in moderate to severe Crohn’s […]

READ MORE >
April 4th, 2017

Innovation Grant Awarded for Qu Biologics Project with University of Ottawa Scientist

Vancouver, British Columbia – April 4th, 2017 – Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a unique platform of immunotherapies designed to “reboot” the body’s innate immune system, has partnered with University of Ottawa Assistant Professor Dr. Adam Shuhendler to address advanced questions regarding trafficking of administered biologics. By nature, biologics, […]

READ MORE >
March 30th, 2017

Qu to Develop Companion Diagnostics for IBD SSI treatment

This article, published in the independent online news platform GenomeWeb on March 23rd 2017,  explores the genetic basis for identifying IBD patients who may best respond to Qu Biologics SSI treatment. GenomeWeb Qu Companion Diagnostics 23MAR17

READ MORE >
March 23rd, 2017

Qu Biologics Discovers that Immune Biomarkers May Predict Response to Novel Immune Therapy for Crohn’s Disease

Vancouver, British Columbia – March 22nd, 2017 – Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a unique platform of immunotherapies designed to restore the body’s innate immune system, has identified immune factors (cytokines and growth factors) in the blood of patients with Crohn’s disease that may predict response to SSI therapy. […]

READ MORE >

Past events:


Past events: